



VIJAYA[®]
DIAGNOSTIC
CENTRE

August 9, 2022

To,
Listing Department
National Stock Exchange of India Limited,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Company Code No. VIJAYA

To,
The Corporate Relations Department
BSE Limited,
Phiroz Jeejeebhoy Towers,
25th Floor, Dalal Street
Mumbai- 400 001
Company Code No. 543350

Dear Sir/Madam,

Sub: Intimation of Press Release.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the "Press Release" being issued by the Company.

Please take the information on record.

Thanking you,

For Vijaya Diagnostic Centre Limited

K. Anusha

Anusha Kanumuru
Company Secretary





**VIJAYA
DIAGNOSTIC
CENTRE**

Regd. Office - 3-6-16 & 17, Street # 19, Himayath Nagar, Hyderabad-29, Telangana

Vijaya Diagnostic Centre Ltd. announces Q1 FY23 Results
Non-COVID Revenues grew by 12% Y-o-Y to Rs. 1,012 Mn
Q1FY23 Radiology share stood higher at 36% as against 32% in Q1FY22
Wellness share in Q1FY23 up at 9.6% as against 4.0% in Q1FY22
Successfully establishes its 100th Diagnostic Centre

Hyderabad, August 9, 2022: Vijaya Diagnostic Centre Limited (NSE: VIJAYA, BSE: 543350), one of India's leading integrated diagnostic chain Company, has announced its financial results for the quarter ended 30th June 2022.

Consolidated Financial Performance:

Particulars (Rs. Mn)	Q1FY23	Q1FY22	YoY	Q4FY22	QoQ
Revenue from Operations	1,044	1,227	-14.9%	1,162	-10.2%
EBITDA	399	569	-29.8%	479	-16.6%
EBITDA Margin (%)	38.2%	46.3%	-810 bps	41.2%	-300 bps
Profit after Tax	175	330	-47.1%	237	-26.4%

Performance Highlights Q1FY23 vs. Q1FY22:

- Revenue from Operations decreased by 14.9% YoY to Rs. 1,044 Mn, Non-COVID Revenues grew by 12% YoY
 - Decline in revenue largely on account of decrease in COVID business. Q1FY23 witnessed a transition in the revenue mix profile from COVID to Non-COVID. This resulted in the Non-COVID business revenues registering a growth of 12% YoY and COVID revenues declining by 90% YoY
 - Radiology business stood higher at 36% as against 32% in Q1FY22 – positively contributing to the Company's non-covid business
 - Wellness share in Q1FY23 was up at 9.6% as against 4.0% in Q1FY22
 - Witnessed positive business momentum in Wellness segment – achieving Pre-COVID levels
- Revenue composition from B2C segment continued to stay strong at 95.0%
- EBITDA stood at Rs. 398.9 Mn. EBITDA margin for the quarter was 38.2%
 - Lower revenues and incremental expenses for upcoming facilities impacted margin performance
 - As new facilities start contributing to performance, the Company anticipates improvement in operating margins
- PAT stood at Rs. 175 Mn. translating into a PAT margin of 16.7%

Commenting on the performance Ms. Suprita Reddy, CEO said, “I am pleased to share that we have commenced the fiscal on a positive note. During Q1FY23, Vijaya was able to capitalize on the healthy recovery in demand from its customers for non-covid, radiology and wellness businesses. A notable month-on-month improvement across our key business parameters was witnessed during this period and we expect this trend to continue in the upcoming quarters as well.

Vijaya has achieved an important milestone of successfully establishing its 100th centre by opening five new centres during Q1FY23. The Company remains excited for its upcoming 10,000 sq.ft facility at Rajahmundry which is expected to be inaugurated soon. Additionally, we made considerable progress on our upcoming 16,000 sq.ft. Punjagutta centre which is scheduled to be launched in the coming months. We remain excited about these state-of-the-art facilities that are well equipped with advanced radiology and will offer a wide range of integrated diagnostics services to our consumers. Overall, our expansion and other growth initiatives are progressing as per plan.

Our endeavor remains on strengthening our leadership position in key markets as we move into the pre-pandemic environment. Looking ahead, we believe that our integrated diagnostics offerings, B2C business model, robust financial position, and strong brand salience in our core markets, should assist us to withstand any near-term challenges. Additionally, we are confident that these inherent strengths would go a long way in creating sustainable value for all our stakeholders.”

-END-

About Us:

Vijaya Diagnostic Centre Limited (VDCL), is the largest integrated diagnostic chain having dominant presence in Southern India. Vijaya provides one-stop solution for pathology and radiology testing services to customers through extensive operational network, which consists of 100 diagnostic centres and 13 reference laboratories across 17 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata. The Company offers comprehensive range of diagnostic services from Basic pathology to high-end radiology.

Corporate Identification No: L85195TG2002PLC039075

Regd. Office: 3-6-16 & 17, Street # 19, Himayath Nagar, Hyderabad-29, Telangana

For more information, please visit www.vijayadiagnostic.com OR contact:

Mr. Siva Rama Raju

Head of Strategy

Vijaya Diagnostic Centre Limited

Tel: +91 99485 95555 / +91 90597 00749

Email: sivaramaraju.v@vijayadiagnostic.in
ir@vijayadiagnostic.in

Anoop Poojari / Devrishi Singh

CDR India

Tel: +91 98330 90434 / +91 98205 30918

Email: anoop@cdr-india.com
devrishi@cdr-india.com

DISCLAIMER:

Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, import duties, litigation, labour relations etc. Actual results might differ substantially from those expressed or implied. Vijaya Diagnostic Centre Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.